← Leaderboards
Laura Perin
Children'S Hospital Of Los Angeles
$5,029,089
Attributed
$7,437,139
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,437,139 · 5
By mechanism
R01$4,749,339 · 2
R44$1,993,146 · 1
R21$457,875 · 1
R43$236,779 · 1
Top collaborators
- Stefano Da Sacco4 shared
- Kristin M Bircsak2 shared
- Morgan Chandler1 shared
Most similar at Children'S Hospital Of Los Angeles
Same institution · by research overlap
- Stefano Da Sacco$3,170,776
- Chintan Parekh$3,618,862
- Benita Tamrazi$1,218,457
- Mark Stephen Borchert$226,875
- Sargis Sedrakyan$732,331
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroCellsRenal FunctionChronic Kidney FailureDisease ProgressionGlomerular Basement MembraneEndothelial CellsPreventGlomerular EndotheliumStructureNovel TherapeuticsGlomerular FiltrationPodocyteHereditary NephritisRenal Glomerular DiseaseInjuryKidney DiseasesIn VivoMolecularInsightMaintenanceInnovationDepositionPathway Interactions
Grant awards (13)
Mechanisms involved in podocyte damage in Alport Syndrome$633,535
R01 · FY2025 · DK · contact PI
Mechanisms involved in podocyte damage in Alport Syndrome$613,580
R01 · FY2024 · DK · contact PI
Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$993,146
R44 · FY2023 · DK
Mechanisms involved in podocyte damage in Alport Syndrome$641,644
R01 · FY2023 · DK · contact PI
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.$525,260
R01 · FY2023 · DK · contact PI
Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$1,000,000
R44 · FY2022 · DK
Mechanisms involved in podocyte damage in Alport Syndrome$697,416
R01 · FY2022 · DK · contact PI
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.$525,260
R01 · FY2022 · DK · contact PI
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.$541,893
R01 · FY2021 · DK · contact PI
Extracellular vesicles derived from amniotic fluid stem cells normalize glomerular function during progressive kidney disease.$570,751
R01 · FY2020 · DK · contact PI
Development of the NephroPlate: A high-throughput kidney-on-a-chip platform for identifying chronic kidney disease therapies$236,779
R43 · FY2020 · DK
A novel approach for the isolation of multipotent pancreas progenitors$208,125
R21 · FY2018 · HD · contact PI
A novel approach for the isolation of multipotent pancreas progenitors$249,750
R21 · FY2017 · HD · contact PI